title: Clinical value of ezrin expression in primary osteosarcoma.
abstract: OBJECTIVE
  Ezrin is a membrane cytoskeletal linker protein and it is known to be associated with metastasis of primary osteosarcoma. The aim of this study is to determine the relationship between an ezrin expression and several key clinical parameters and to elucidate its potential prognostic value for patients with osteosarcoma.
  
  
  METHODS
  Seventy patients with histologically confirmed osteosarcoma and who had no distant metastasis were enrolled between 1995 and 2005 at Yonsei Cancer Center, Severance Hospital, Korea. The clinical parameters were retrospectively reviewed and immunohistochemical staining (IHC) for ezrin was performed using the surgically resected specimens.
  
  
  RESULTS
  Of the 70 tumor specimens, 39 (55.7%) revealed an ezrin expression. More of an osteoblastic histology and an elevated initial ALP level were observed in the ezrin positive patients than in the ezrin negative patients (p=0.008 and 0.001, respectively). The proportion of patients who favorably responded to neoadjuvant chemotherapy (≥or=90% necrosis) was significantly higher in the group of ezrin positive patients than that in the group of ezrin negative patient (72.2% vs 45.2%, respectively, p=0.024). The ezrin positive patients showed more frequent recurrence than did the ezrin negative patients (64.1% vs 35.5%, respectively, p=0.017). The patients with an ezrin expression also demonstrated poorer survival than did those patients without ezrin expression (5-year EFS: 31.7% vs 61.3%, respectively, p=0.023, 5-year OS: 53.4% vs 71.0%, respectively, p=0.022). When comparing EFS according to both an ezrin expression and chemoresponsiveness, there were trends that the ezrin negative/chemoresponsive group showed the best 5-year EFS (71.4%), followed by the ezrin negative/chemoresistant group (52.9%), the ezrin positive/chemoresponsive group (38.1%) and the ezrin positive/chemoresistant group (13.6%). These trends were statistically significant (p=0.036).
  
  
  CONCLUSIONS
  The expression of ezrin by IHC staining was found in 55.7% of the patients with metastasis-free osteosarcoma. Immunoreactivity to ezrin is a negative prognostic factor for survival for the patients suffering with osteosarcoma. Identifying an ezrin expression might offer a valuable piece of information when treating patients with primary osteosarcoma.
authors.affiliation: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
authors.forename: Chan
authors.initials: C
authors.lastname: Kim
authors.forename: Eunah
authors.initials: E
authors.lastname: Shin
authors.forename: Soojung
authors.initials: S
authors.lastname: Hong
authors.forename: Hong Jae
authors.initials: HJ
authors.lastname: Chon
authors.forename: Hye Ryun
authors.initials: HR
authors.lastname: Kim
authors.forename: Jung Ryun
authors.initials: JR
authors.lastname: Ahn
authors.forename: Min Hee
authors.initials: MH
authors.lastname: Hong
authors.forename: Woo Ick
authors.initials: WI
authors.lastname: Yang
authors.forename: Jae Kyung
authors.initials: JK
authors.lastname: Roh
authors.forename: Sun Young
authors.initials: SY
authors.lastname: Rha